Acute Hepatic Porphyria Therapeutics
1. Givlaari patent expiration
Treatment: Treatment of acute hepatic porphyria
GIVLAARI's oppositions filed in EPO
GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(2 years ago) | |
| US8546143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of a target gene |
Jan, 2022
(4 years ago) | |
| US10131907 | ALNYLAM PHARMS INC | Glycoconjugates of RNA interference agents |
Aug, 2028
(2 years from now) | |
| US8106022 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2029
(3 years from now) | |
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(8 years from now) | |
| US8828956 | ALNYLAM PHARMS INC | Carbohydrate conjugates as delivery agents for oligonucleotides |
Dec, 2028
(2 years from now) | |
| US10125364 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(7 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(8 years from now) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(1 year, 7 months ago) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 10 months ago) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 10 months ago) | |
| US9133461 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Nov, 2033
(7 years from now) | |
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9631193 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Mar, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
